A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Nov 4, 2023

IZERVAY^TM (avacincaptad pegol intravitreal solution) Monthly or Every Other Month Reduced Geographic Atrophy Lesion Growth Through 2 Years

-Phase 3 results presented at the AAO Annual Meeting demonstrated the IZERVAY treatment effect more than doubled over 2 years compared to 1 year-

TOKYO, November 4, 2023 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced results from the GATHER2 Phase 3 clinical trial, demonstrating IZERVAY™ (avacincaptad pegol intravitreal solution) continued to reduce the rate of geographic atrophy (GA) lesion growth for both...

Read more about IZERVAY^TM (avacincaptad pegol intravitreal solution) Monthly or Every Other Month Reduced Geographic Atrophy Lesion Growth Through 2 Years
Oct 25, 2023

Astellas Ranked First in Pharmaceuticals Sector of “2023 Award for Excellence in Corporate Disclosure” by Securities Analysts Association of Japan

TOKYO, October 25, 2023 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the company has ranked first in the pharmaceuticals sector for the “2023 Award for Excellence in Corporate Disclosure” granted by the Securities Analysts Association of Japan (SAAJ) to...

Read more about Astellas Ranked First in Pharmaceuticals Sector of “2023 Award for Excellence in Corporate Disclosure” by Securities Analysts Association of Japan
Oct 22, 2023

Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV^®(enfortumab vedotin-ejfv) and KEYTRUDA^® (pembrolizumab) in First-Line Advanced Bladder Cancer

– Risk of death was reduced by 53% in patients treated with enfortumab vedotin plus pembrolizumab compared to chemotherapy –

TOKYO and BOTHELL, Wash. – October 22, 2023 -- Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, “Astellas”) and Seagen Inc. (Nasdaq: SGEN) today announced results from the Phase 3 EV-302 clinical trial (also known as KEYNOTE-A39) for PADCEV® (enfortumab vedotin-ejfv) in combination...

Read more about Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV^®(enfortumab vedotin-ejfv) and KEYTRUDA^® (pembrolizumab) in First-Line Advanced Bladder Cancer
Oct 15, 2023

Astellas to Share New Data Across Hard-to-Treat Cancers During ESMO Congress 2023

Data include three late-breaking abstracts, underscoring Astellas’ efforts to potentially redefine expectations for patients across its oncology portfolio

TOKYO, Oct 15, 2023 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) will share new research results during the European Society for Medical Oncology (ESMO) Congress 2023 from October 20-24, showcasing the company’s focus on making a meaningful difference for people living with...

Read more about Astellas to Share New Data Across Hard-to-Treat Cancers During ESMO Congress 2023
Oct 13, 2023

Astellas Receives Positive CHMP Opinion for VEOZA^TM (fezolinetant)

Fezolinetant is an investigational nonhormonal treatment for vasomotor symptoms (VMS) associated with menopause

TOKYO, October 13, 2023 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) on October 12 adopted a positive opinion relating to the use of VEOZA™ (fezolinetant) 45 mg...

Read more about Astellas Receives Positive CHMP Opinion for VEOZA^TM (fezolinetant)

Show per page

Discover more

Media contacts

Return to media homepage

Subscribe to news alerts

Choose Language

News